Zim Labs Q4 & FY26: Revenue Down, EBITDA Declines

Zim Laboratories Ltd has announced its Q4 and FY26 earnings presentation. The company's FY26 total operating income decreased by 1.2% to ₹3,744 Mn, with EBITDA down 16.4% to ₹414 Mn. The EBITDA margin was 11.1%. Q4FY26 total operating income fell by 3.2% to ₹1,053 Mn, with EBITDA decreasing by 18.1% to ₹134 Mn and an EBITDA margin of 12.7%. Total R&D spend for FY26 was ₹311 Mn and ₹81 Mn for Q4FY26.